Seizure in Medical Technology
Navigation Links
Seizure in Medical Technology
... resulted
in a marked and sustained decrease in seizure frequency over the long-term(1).
Results ... add-on treatment experienced a
mean reduction in seizure frequency of more than 61% (95%CI: ... had achieved at least a 50% reduction in seizure frequency with
Zebinix(R) treatment(1).
...
... treatment success is not only determined by seizure control, but equally by tolerability, which is ... demonstrate benefit of carisbamate in reducing seizure frequency in some patients with partial onset ... endpoints were median percent reduction in seizure frequency in the double blind phase compared to ...
... Ohio. "Existing antiepileptics offer limited seizure control and there may be difficulties with ... AEDs. The median percentage reduction in total seizure frequency from baseline was greater in the ... 42.5% median percentage reduction in tonic-atonic seizure (drop attack) frequency per 28 days from baseline ...
... Keppra XR(TM) significantly reduced partial onset seizure frequency when administered as adjunctive ... tablets significantly reduced partial onset seizure frequency when administered as adjunctive therapy ... The study met its primary endpoint for seizure reduction over placebo during the treatment ...
... XR achieved at least a 50 percent reduction in seizure frequency compared to 24 percent of patients ... XR taken once- daily significantly reduced seizure frequency among previously uncontrolled patients. ... median percent reduction from baseline in partial seizure frequency. Study results showed that Lamictal ...
... NUCYNTA(TM) has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical studies. NUCYNTA(TM) should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures. ...
... RISPERDAL(R) CONSTA(R) should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that ... with a history of seizures or with conditions that potentially lower seizure threshold. Dysphagia: Esophageal dysmotility and aspiration can ...
... included. These variations can mean the difference between being seizure free and suddenly having a seizure while driving on the freeway," said Dr. Brien Smith, Senior Staff ...
... oral antiepileptic drug. In these circumstances, and in order to maintain seizure control, a short-term, alternative administration of their antiepileptic ... significantly greater 50% responder rates and reductions in median seizure frequency were seen versus placebo. The most common adverse events of ...
... before talking to your healthcare professional. Avoid alcohol while on paliperidone. Paliperidone should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures. Extrapyramidal Symptoms (EPS) are ...
... by recurrent, unprovoked seizures, is a change in sensation, awareness or behavior caused by an electrical disturbance in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the disturbance. Primary generalized seizures involve the entire brain ...
... to other erythropoietic proteins. The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some ...
... erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In ...
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
... Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International ...
... Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International ...
... seizures (ARS) are bouts of acute seizure activity occurring within a 24-hour period in adults and a 12-hour period in children. ARS, also called seizure clusters, occurs in a small subset of patients with epilepsy who regularly experience breakthrough seizures in flurries or clusters despite treatment ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... in helping patients move closer to the goal of seizure freedom," said Steven S. Chung, MD, Director of ... those recently diagnosed who have not achieved seizure control on current therapy, to those who have ... with epilepsy, less than half (47%) attained seizure control with the first AED More than 30% ...... treatment success is not only determined by seizure control, but equally by tolerability, which is ... demonstrate benefit of carisbamate in reducing seizure frequency in some patients with partial onset ... endpoints were median percent reduction in seizure frequency in the double blind phase compared to ...
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
... and demonstrated sustained reduction in partial seizure frequency during a one-year open label ... a patient's day-to-day life, as well as effective seizure control," said Professor E. Ben-Menachem, ... Sweden. "In addition to sustained reductions in seizure frequency, Zebinix(TM) also demonstrated ...... Ohio. "Existing antiepileptics offer limited seizure control and there may be difficulties with ... AEDs. The median percentage reduction in total seizure frequency from baseline was greater in the ... 42.5% median percentage reduction in tonic-atonic seizure (drop attack) frequency per 28 days from baseline ...
Status of the E2007 (perampanel) Development Program
... pentylenetetrazole, audiogenic and kindling seizure models) suggested that perampanel may ... seizures. There was a 40% median seizure reduction in the perampanel arm and a 2% median seizure increase in the placebo arm. The responder rate, ...Keppra XR(TM) Extended-Release Tablets Filed with the FDA
... The study met its primary endpoint for seizure reduction over placebo during the treatment ... to the extended-release levetiracetam group had seizure frequency per week reduced by 75-100%, compared ... seizures and 8.9% were free from any type of seizure over the treatment period, compared to 2.5% and ....... Keppra XR(TM) significantly reduced partial onset seizure frequency when administered as adjunctive ... tablets significantly reduced partial onset seizure frequency when administered as adjunctive therapy ... The study met its primary endpoint for seizure reduction over placebo during the treatment ...
... XR achieved at least a 50 percent reduction in seizure frequency compared to 24 percent of patients ... XR taken once- daily significantly reduced seizure frequency among previously uncontrolled patients. ... median percent reduction from baseline in partial seizure frequency. Study results showed that Lamictal ...
... NUCYNTA(TM) has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical studies. NUCYNTA(TM) should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures. ...
... RISPERDAL(R) CONSTA(R) should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that ... with a history of seizures or with conditions that potentially lower seizure threshold. Dysphagia: Esophageal dysmotility and aspiration can ...
... included. These variations can mean the difference between being seizure free and suddenly having a seizure while driving on the freeway," said Dr. Brien Smith, Senior Staff ...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... should be gradually withdrawn to minimize the potential of increased seizure frequency. Dosing must be individualized according to the ... and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Forty percent of patients taking only one ...... oral antiepileptic drug. In these circumstances, and in order to maintain seizure control, a short-term, alternative administration of their antiepileptic ... significantly greater 50% responder rates and reductions in median seizure frequency were seen versus placebo. The most common adverse events of ...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... a car, operating machines, or doing things that require you to be alert. INVEGA((R)) SUSTENNA(TM) should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures. Call your doctor right away if you ...Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...... before talking to your healthcare professional. Avoid alcohol while on paliperidone. Paliperidone should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures. Extrapyramidal Symptoms (EPS) are ...
... by recurrent, unprovoked seizures, is a change in sensation, awareness or behavior caused by an electrical disturbance in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the disturbance. Primary generalized seizures involve the entire brain ...
... to other erythropoietic proteins. The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some ...
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
... potentially hazardous tasks such as driving a car or operating machinery. Tapentadol should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures. The development of a potentially life-threatening serotonin ...... erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In ...
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
... management, as clinically indicated. Carbapenems may reduce serum valproic acid concentrations to subtherapeutic levels, resulting in loss of seizure control. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or ...... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
... management, as clinically indicated. Carbapenems may reduce serum valproic acid concentrations to subtherapeutic levels, resulting in loss of seizure control. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or ...... Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International ...
... Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
... allergic reactions have been seen in some patients during ELAPRASE infusions. Reactions included difficulty breathing, lack of oxygen, seizure or loss of consciousness, hives, and/or swelling of the throat or tongue. Patients received an antihistamine to reverse the allergic reaction or ...Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with Cimzia(R); the causal relationship to Cimzia(R) ...... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
... Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International ...
... seizures (ARS) are bouts of acute seizure activity occurring within a 24-hour period in adults and a 12-hour period in children. ARS, also called seizure clusters, occurs in a small subset of patients with epilepsy who regularly experience breakthrough seizures in flurries or clusters despite treatment ...
PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...This Thanksgiving Give the Gift of Good Health - Remind Family and Friends to Get a Flu Shot.
... cancer treatments) -- Adults and children who have certain muscle or nerve disorders (e.g. cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can ...Other ContentsincontinenceincontinenceincontinenceincontinencetracttracttracttracttracttracttracttracturinationurinationurinationchemistrychemistrychemistrychemistrychemistrychemistrychemistrychemistrychemistrychemistrycollectioncollectioncollectioncollectioncollectioncollectioncollectioncollectioncollectionoutputoutputoutputoutputoutputoutputoutputoutputgravitygravitygravitygravitygravityurologyurologyurologyurologyurologyOther TagsevoevoevoevoevoevoevoevothingthingthingthingOther Tagsshrinking 2eliminating 2eliminating 3eliminating 4eliminating 5eliminating 6eliminating 7eliminating 8accelerate 2accelerate 3accelerate 4accelerate 5accelerate 6accelerate 7enhancing 2enhancing 3enhancing 4enhancing 5enhancing 6enhancing 7was 2was 3was 4was 5was 6was 7was 8was 9was 10avian 2avian 3avian 4avian 5experimental 2experimental 3experimental 4experimental 5experimental 6experimental 7experimental 8experimental 9experimental 10trial 2trial 3trial 4trial 5trial 6trial 7trial 8trial 9trial 10initiates 2
(Date:11/23/2009)... "incontrovertible evidence" that the volcanic sup... 73,000 years ago deforested much of central India... report. , The volcano ejected an estimated 800 ...ng a crater (now the world,s largest volcanic lake...de. Ash from the event has been found in India, th...
(Date:11/23/2009)...OE and USDA study concluded that 50 million U.S. a...ure could be converted from current uses to the pr..., from which biomass could be harvested for use as...on of a perennial grass monoculture from which sub...y is expected to require nitrogen fertilizer. , ...
(Date:11/23/2009)... in unprecedented detail how the ribosome interact...d guide them toward their destination in biologica...ble fitting (MDFF) to examine the interaction of t... , The first study, in Proceedings of the Nati...ignaling between the ribosome and an elongation fa...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Switchgrass produces biomass efficiently 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 1Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 2Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 3Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 4Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 5Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 6Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 7Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 8Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 9Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 10Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 11Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 12Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 13Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 14Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 15Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 16Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 17Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 18Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 19Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 20Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 21Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 22Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 23Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 24Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 25Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 26Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 27Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 28Boston Scientific Announces Results for Third Quarter Ended September 30 2009 5573 29WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 5569 1WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 5569 2FDA Approves New Treatment for Advanced Form of Kidney Cancer 5565 1FDA Approves New Treatment for Advanced Form of Kidney Cancer 5565 2(Date:11/24/2009)...November24/PRNewswire-FirstCall/--ICL(TASE:ICL),a,...y,todayreported,resultsforthethirdquarterandninemo...fortheThirdQuarter , Revenues:Revenuesforthet...dsequentiallywith$1,083millionforthesecondquartero...illion,reflecting,theexceptionaldemandandpricestha...
(Date:11/24/2009)... Slate and New Markets build on their combined st...r. , Baltimore, Md. (PRWE...slatecap.com ), a private equity firm based in Bal... ( www.newmarketsvp.com ), a venture capital firm ...hat they have acquired Ecoast Sales Solutions, Ltd...
(Date:11/24/2009)... The GeoPense World Volunteer Computing Team has ...the Quantum Monte Carlo method to problems in Quan...s important in life science research. This project...Einstein@home (gravity wave detection), and GPUGr... , (PRWEB) November 24, 2...
(Date:11/24/2009)... NCL Security Launches EyeCentral Remote Video Pl...ring Monthly Revenue for Central Stations and Secu...exas (PRWEB) November 24, 2009 -- NCL Security Lau...urity Industry to Generate Recurring Monthly Reven..."Integrated security systems has been and sti...
(Date:11/23/2009)...ember 18, 2009 -- A team of researchers at the Uni...ersity has developed a way to simulate blood flow ...s the basis of a new tool that may help surgeons p..." surgery, which is performed on babies born with ...ers will present their work next week at the 62nd ...
Breaking Medicine News(10 mins):Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 3Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 4Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 5Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 6Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 7Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3Health News:GeoPense Announces it has Joined QMC@home Project 2Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:New tool for helping pediatric heart surgery 2[0] ICL Reports Continued Sequential Improvement for Third Quarter of 2009[0] Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions[0] GeoPense Announces it has Joined QMC@home Project [0] NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers[0] New tool for helping pediatric heart surgery
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |